Cell surface binding and cellular internalization properties of suramin, a novel antineoplastic agent

Area of Science:

• Pharmacology
• Cell Biology
• Cancer Research

Background:

• Suramin shows antineoplastic potential in preliminary clinical trials.
• The precise mechanism of suramin's action (extracellular vs. intracellular) remains unclear.
• Understanding suramin's cellular pharmacology is crucial for optimizing its therapeutic use.

Purpose of the Study:

• To investigate the cellular pharmacology of suramin in prostate cancer (DU145, LNCaP) and leukemia (HL60) cell lines.
• To determine the binding characteristics and internalization pathways of suramin.
• To elucidate the influence of cell type on suramin's cellular uptake and efflux.

Main Methods:

• Utilized tritiated suramin ([3H]suramin) to study cellular uptake and binding.
• Employed competitive binding assays with a cytidine phosphorothioate oligodeoxynucleotide and ATP.
• Investigated suramin internalization via adsorptive endocytosis and exocytosis kinetics.

Main Results:

• Observed significant, low-affinity, trypsin-insensitive cell surface binding of [3H]suramin across all cell lines.
• HL60 cells internalized suramin via adsorptive endocytosis, while prostate cancer cells showed differential binding inhibition by albumin and temperature.
• DU145 cells exhibited concentration- and time-dependent suramin internalization with biphasic exocytosis from endosomal compartments.

Conclusions:

• Suramin exhibits complex cellular pharmacology with distinct binding and internalization patterns.
• Cell type significantly influences suramin's interaction with cell surfaces and its subsequent intracellular fate.
• The varied cellular pharmacology suggests that suramin's mechanism of action may differ across cancer types.